Introduction
Asthma is a disease of chronic airway inflammation, which is unique in that the airway wall is infiltrated by T lymphocytes, eosinophils, macrophages/monocytes mast cells, and sometimes by neutrophils (1) . In parallel with the chronic inflammatory process, airways remodeling characterized by an increase in muscle mass, mucous glands, vessel area as well as thickening of the reticular basement membrane, is almost always present in biopsies of the asthmatics (2) . Among these, airway smooth muscle (ASM) is subject to a dominant pathological change. In addition to contractile properties, ASM may contribute to airway inflammation of asthma by expression and secretion of pro-inflammatory cytokines and mediators, such as eotoxin (3) and IL-5 (4). In asthmatic airway remodeling, the mechanism of phenotype change in ASM has not yet been clear.
Neutrophils have been recovered in the airways of asthmatics, although their role in the pathogenesis of asthma remains unclear. The number of airway neutrophil increases during the late-phase response after an allergen challenge (5) , in some patients who died within hours after an asthma exacerbation (6) and in some patients with long-standing asthma (7) . Neutrophil-derived elastase (NE) is a serine protease involved in host defense against bacterial pathogens (8) . NE is capable of hydrolyzing a broad spectrum of extracellular matrix (ECM) and cellular proteins, such as elastin, interstitial collagens, proteoglycans, fibronectin, laminin, and others (9) . Increasing evidence also indicates that NE can provoke a variety of cellular responses. For instance, NE has been identified to induce the expression of IL-8 (10) and secretory leukocyte protease inhibitor (SLPI) (11) in epithelial cells, and to induce ASM cell proliferation (12) .
Transforming growth factor-(TGF-), made up of 3 iso-forms (TGF-1,2,3), is a multifunctional cytokine contributing to the initiation and resolution of inflammatory events, impacting on the cell growth, and playing an important role in tissue repair and fibrosis (13) . Compared with normal subjects, TGF-concentrations are higher in bronchoalveolar lavage fluid of asthmatics (14) . TGF-gene expression is upregulated in bronchial tissue from severe asthmatic patients (15) and has been demonstrated to correlate with the thickness of subepithelial basement membrane.
Thus, TGF-may contribute to the pathogenesis of airway remodeling in asthma (16) .
NF-B is a transcription factor of particular importance in immune and inflammatory responses (17) . The activated form of NF-B is a heterodimer consisting of two proteins, a p65 subunit and a p50 subunit, or other subunits (rel, rel-B, p52, v-rel) (18) . In unstimulated cells, NF-B is found in cytoplasm bound to I Bs. Stimulation with cytokines, reactive oxygen species, and microorganisms, induces phosphorylation and degradation of I Bs, followed by translocation of 6 NF-B to the nucleus, binding to its response elements in promoters and leading to transcriptional initiation of responsive genes (19) .
In the present study, we have examined the role of NE as an inducer of cytokine production by ASM. We demonstrated that NE enhanced the release of TGF-1 in primary cultures of human ASM cells. By using quantitative real-time reverse transcriptase-polymerase chain reaction (RT-QPCR), we also revealed an increase in mRNA level and provided evidence that a transcriptional and translational mechanism was involved. Furthermore, the NE induced ASM TGF-1 secretion was preceded by activation of NF-B and was blocked by pretreatment with NF-B inhibitors. Finally, we showed a rapid association of MyD88 and IRAK following NE stimulation. These findings demonstrate that NE activates the MyD88/IRAK/NF-B pathway in generation of TGF-1 from ASM.
Methods

Human ASM Cell Preparation
The human bronchial smooth muscle cells (hBSMC, Clonetics Corporation, San Diego, CA) were cultured in 25cm 2 flasks, in culture medium for hBSMCs supplemented with 10% FBS (fetal bovine serum), human epidermal growth factor (hEGF, 0.5g/ml), insulin (5 mg/ml), human fibroblast growth factor (hFGF, 1µg/ml), gentamicin (50µg/ml), and amphotericin B (0.05µg/ml) (SmGM-2 BulletKit, Clonetics) at 37°C, 5% CO2. When the cells became confluent, they were subcultured in the same medium. At confluence, cells obtained from 25 cm 2 flasks were passaged using 0.25% trypsin in 0.02% EDTA. Medium was changed every other day. Cells before confluence at passages 3 to 7 were detached from culture flasks with 0.25% trypsin in 0.02% EDTA and were used for later experiments. Confluent cells were growth arrested in serum-free DMEM for 24 hours before experiments. ASM cell number counted by a hemocytometer and DNA synthesis (12) did not increase [6] [7] [8] [9] [10] [11] [12] hours after stimulation with human neutrophil elastase (NE, 0.01, 0.05, 0.1, and 0.5µg/ml). The cellular viability was determined by MTT assay (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's instructions.
Reagents
Human neutrophil-derived elastase (NE), Actinomycin D, Cycloheximide, pyrrolidine 
NE activity assay
To investigate the effects of chromogenic substrate for NE, NE at final concentrations of (0.01-1 µg/ml) was added to assay buffer (0.45M Tri-Base, 2M NaCl, pH 8.0) and elastase substrate I (MeOSuc-Ala-Pro-Val-pNA) (Calbiochem, La Jolla, CA) for 5 min. The cleavage was monitored at 410nm spectrophotometer and the slope for NE activity was determined.
Quantification of TGF-1 Protein Production
The concentrations of TGF-1 in supernatants were measured with specific ELISA kits (R&D System, Minneapolis, MN) using the quantitative immunometric sandwich enzyme immunoassay technique. For the assay, the frozen supernatants prepared from cultured ASM were thawed at room temperature and were first activated by incubated 
Western Blot Analysis
Cytoplasmic and nuclear extracts were subjected to SDS-polyacrylamide gel electrophoresis and blotted onto nitrocellulose filters. NF-B subunit p65 was detected with a mouse anti-human p65 antibody (Transduction Laboratories) and an alkaline phosphatase-conjugated anti-mouse antibody. Phosphorylated I B was detected with a rabbit anti-human phosphor-I B antibody (Cell Signaling Technology Inc) and an alkaline phosphatase-conjugated anti-rabbit antibody.
TLR4 protein was detected on total protein of ASM cells after exposure to NE (0.5 µg/ml) for 20 min with a mouse IgG2A anti-human TLR4 antibody (Serotec) and an alkaline phosphatase-conjugated anti-rabbit antibody. Blots were developed by adding of 5-bromo-4-chloro-3-indole phosphate/nitroblue tetrazolium solution (Sigma) and were then exposed to XAR-5 film.
Flowcytometric Analysis of TLR4 and PAR2 expression
To quantify TLR4 ዊዊዊዊPAR2 cell surface expression, ASM cells were seeded in eight-well chamber slides in serum-free medium for 24 h prior to exposure to NE (0. 
Coimmunoprecipitation
ASM cells plated on 10-cm dishes were treated with 0.5 µg/ml NE for variable times (from 0 to 10 min). The cells were than harvested, lysed in 200 µl of PD buffer (40 mM Tris-HCl, pH8.0, 500 mM Nacl, 0.1% Nonidet P-40, 6 mM EGTA, 10 mM -glycerophosphate, 10 mM NaF, 300 µM sodium orthovanadate, 2 mM PMSF, 10 µl/ml aprotinin, 1 µg/ml leupeptin, and 1 mM DTT), and centrifuged. The supernatant was then immunoprecipitated with a polyclonal antibody against MyD88 (eBioscience) in the presence of A/G-agarose beads overnight at 4°C. The immunoprecipitated beads were then washed three times with PD buffer. The sample were fractionated on 7.5% SDS-PAGE, transferred to nitrocellulose membrane, and subjected to immunoblot analysis with human interleukin-1 receptor-associated kinase (IRAK) (Calbiochem, La Jolla, CA) and MyD88 antibodies.
Statistical Analysis
Data were analyzed with the GraphPad Prism 3.0 software package (GraphPad Software, San Diego, CA). Results are expressed as mean ± S.E. Unpaired comparison was analyzed by Mann-Whitney U test. In the time course study of TGF-1 mRNA induction one way ANOVA with Dunnet's multiple comparison post-test was used to validate the trend. Differences were considered significant when the p value wasዊ0.05.
Results
NE induces TGF-1 secretion
To determine the effect of NE on TGF-1 release, confluent, growth-arrested ASM cells were treated with different concentrations of NE (0.01, 0.05, 0.1, and 0.5µg/ml) or untreated for 6 hours. NE at the concentration of 0.5µg/ml significantly increased TGF-1 concentration (316.2ዊ68.8 pg/ml) compared to the basal level (58.5ዊ19.0 pg/ml, n=5, p< 0.01) (Fig 1A) . Exposure of ASM cells to higher concentrations of NE (1 or 5 µg/ml) were excluded from the present study due to a high magnitude of cellular toxicity determined by MTT assay. Although the effect of NE on TGF-1 production was not dose-dependent, the purity assay of NE activity showed a dose-dependent cleavage effect on chromogenic substrate (data not shown).
ELISA assay for TGF-1 protein detects both active and non-active forms of TGF-1.
However, no spontaneous active form was detectable without pre-acidification of the culture supernatants in the presence or absence of NE. Incubation of the supernatant of untreated ASM cells with NE (0.5 µg/ml) for 6 hours did not affect the basal level of TGF-1 (50.3+18.7, n=4) when compared with those in the absence of NE (51.0+20.3, n=4).
To determine whether the enhanced TGF-1 secretion is due to the NE specific activity, NE was used in the presence of a potent irreversible inhibitor of human neutrophil elastase, Elastase inhibitor II (EI II), or a protease inhibitor cocktail (PI).
Either pretreatment with Elastase inhibitor II (100 µg/ml) or a protease inhibitor cocktail resulted in complete inhibition of the NE-mediated release of TGF-1.
The time course of TGF-1 secretion from ASM cells is shown in Fig 1B. In the absence of NE, there was a constitutive TGF-1 production increasing from 6 hours, 12 hours to 24 hours (58.2ዊ19.0 pg/ml, 87.3+56.1 pg/ml and 158.1ዊ80.8 pg/ml respectively, n=5, p<0.01). NE increased TGF-1 production significantly at 6 hours (166.4ዊ36.2 pg/ml) and continued to enhance the production to 288.5+64.3 pg/ml at 12 hours and 494.2ዊ73.7 pg/ml at 24 hours (p<0.01 compared to control ASM cells at comparative time points). Since there was a significant increase in cell number after incubation with NE for 24 hours, longer time culture was not further examined. (Fig. 2A) . These data suggest that the NE-induced TGF-1 release involves both transcription and translation mechanisms.
To further confirm an increase in transcription, TGF-1 mRNA was measured by RT-QPCR. Fig. 2B demonstrates that NE time-dependently induced TGF-1 mRNA accumulation, with a maximal and significant induction of 2.3ዊ0.7-fold at 4 hours (p<0.01 by one way ANOVA with Dunnett's multiple comparison test) during the study period.
NE-induced TGF-1 expression involves NF-B activation
NE induces NF-B activation in bronchial epithelial cells (20) . We therefore explored which signal pathways mediate the NE-induced TGF-1 gene up-regulation. ASM cells were left untreated or stimulated with 0.5 µg/ml NE with or without pretreatment by pyrrolidine dithiocarbamate (PDTC, 1mM), a non-specific NF-B inhibitor, aspirin (Asp, 2.5 mM) or sodium salicylate (NaSal, 2.5mM), both inhibitors of I B kinase-(21), for 30 minutes. As shown in Fig. 3 , pre-incubation with PDTC, aspirin, or NaSal abolished the NE-induced TGF-1 production (144.7ዊ31.2 pg/ml, n=5, p<0.01; 210.4ዊ46.3 pg/ml, n=5, p<0.05; 144.8ዊ10.4 pg/ml, n=5, p<0.01, respectively), suggesting NF-B was mediated in NE-induced TGF-1 secretion.
Upon NE stimulation (0.5 µg/ml), phosphorylation of I B-rapidly occurred at 5 minutes (Fig. 4A) , followed by an increase in nuclear p65 by 2.5±0.9 folds (Fig. 4B, p<0 .05, n=3) at 10 minutes and returned to the basal levels at 30 minutes. These data demonstrate that p65 was released from the cytoplasm and translocated to the nucleus by NE stimulation.
To directly determine NF-B activation, we used reporter gene assays. ASM cells were transiently transfected with pNF-B-d2EGFP. 18 hours after transfection, the cells were treated with 0.5 µg/ml NE for 4 hours and the fluorescence intensity of the transfected cells was examined by fluorescence microscopy. Transfection efficiency was determined by transfection with pEGFP-C2. As shown in Fig. 5A-5D , NE-stimulated cells appeared strong d2EGPF fluorescence intensity, suggesting an augmentation in NF-B transactivation activity. To further quantify this activity, we used flow cytometry to measure fluorescence intensity. We found a 1.8ዊ0.1-fold increase in mean fluorescence intensity (MFI) in the NE-treated cells compared with unstimulated cells (Fig. 5E, n=5, p<0 .01). These results confirm the observation of NF-B activation in Western Blotting.
NE stimulates IRAK activation in ASM cells
MyD88/IRAK/TRAF pathway, an upstream NF-B signal pathway, has been proved to mediate the NE-induced IL-8 up-regulation in human bronchial epithelium (20), we next examined whether NE stimulates IRAK activation in ASM by using co-IP. Upon stimulation with NE (0.5 µg/ml), IRAK was rapidly associated with MyD88 as early at 5 min and partially sustained at 10 min (Fig. 6 ). This kinetics is temporally in agreement with that of I B-phorylation and NF-B activation and suggests that MyD88/IRAK pathway is the upstream pathway of NF-B-mediated TGF-1 gene expression by NE stimulation.
NE-stimulated TGF-1 secretion is not mediated by IL-1 or IL-1
IRAK was first described as a signal transducer for the proinflammatory cytokine interleukin-1 (IL-1) and was later implicated in signal transduction of other members of the Toll-like receptor (TLR)/IL-1 receptor (IL-1R) family (22) . We next asked whether IL-1 and IL-1R are involved in the up-regulation of TGF-1 production by NE. ASM cells were pretreated with or without neutralizing antibodies against IL-1 (0.1 or 1 µg/ml), IL-1 (0.1 or 1 µg/ml), IL-1RI (0.1, 1, 10 µg/ml) and IL-1RII (0.1, 1, 10 µg/ml) for 30 min, followed by NE stimulation (0.5 µg/ml) or let untreated for 6 h.
By ELISA, we failed to find any inhibition effect on NE-induced TGF-1 release with these neutralizing antibodies. In addition, there was no detectable level of IL-1 , or IL-1 in the supernatants of NE-stimulated ASM (data not shown). These results exclude the involvement of IL-1 and IL-1 receptors in the NE induction of TGF-1 secretion.
NE decrease expression of TLR4
Furthermore, NE was shown to activate NF-B through TLR4 (23), via IRAK/MyD88/TRAF6 pathway (20) . In subsequent experiments, TLR4 protein expression on ASM cell surface was analyzed by flowcytometry, and was found decreased after NE (0.5 µg/ml) treatment (Fig. 7A) . Western blot analysis of TLR4 protein on ASM cells was also decreased with NE (0.5 µg/ml) (Fig. 7B) . Pretreatment with a blocking antibody to TLR4, but not PAR2, attenuated the effect of NE (0.5 µg/ml) on TGF-1 production (Fig. 7C) (Fig. 8B) . NE did not affect the expression of PAR2 on ASM cells (Fig. 8A) .
Discussion
This is the first study showing that NE enhances TGF-1 gene expression and protein production in human ASM cells. Given that the NE-stimulated response was inhibited by actinomycin D or cycloheximide, the NE-induced TGF-1 production involves de novo protein production. Upon NE stimulation, I B was rapidly phosphorylated, followed by p65 nuclear translocation. The fact that pretreatment with variable NF-B inhibitors prevented the NE-induced TGF-1 release further supports the role of NF-B. NE increased association of IRAK with MyD88, which has been shown to be followed by induction of MyD88/IRAK/TRAF-6 (tumor necrosis factor receptor-associated factor 6) pathway and in turn activation of NIK and NF-B activation (24, 25) . NE has been reported to exhibit several functions in addition to its proteolytic activity, such as induction of IL-8 (10) . In the present study, the NE-induced TGF-1 production was maximal with NE at 0.5 µg/ml. Higher concentration of NE was not further examined due to a high magnitude of cellular toxicity. The dose-dependent cleavage effect on chromogenic substrate confirms the purity of NE used in this study, and stands against the possibility that impurity of NE results in a lack of dose-response effect of NE. TGF-1 is secreted in latent forms and becomes active after cleavage by proteolytic enzymes (13) . TGF-1 was measured by using an ELISA (26) and from mouse lungs (27) suggest that elastase has the potential to up-regulate TGF-1 at multiple levels, transcriptioanlly in cells and posttranslationally in extracellular storage sites.
In this report, we show that NF-B is involved in the NE enhancement of TGF-1 expression. NE-induced TGF-1 release was inhibited by the NF-B inhibitor PDTC, aspirin and sodium salicylate, compounds with anti-IKK activity. By using Western blotting, we clearly demonstrated that NE induced I B phosphorylation and p65 nuclear translocation. Reporter gene assays further confirmed the activation of this transcription factor. Importantly, a NF-B response element in the TGF-1 promoter has recently been identified which was shown to mediate TGF-1 transcription stimulated by IL-1 (26) . Our data are also in agreement with the finding that treatment with relA antisense oligonucleotides inhibited TGF-1 mRNA expression in fibrosarcoma cells (28) and monocytes from patients with idiopathic myelofibrosis (29) . In the latter study, IL-1 was argued to be released following NF-B activation and then autostimulate the production of TGF-1 (29) . Our findings that there was no detectable IL-1 or IL-1 in culture supernatants after NE treatment, and that pretreatments of cells with blocking antibodies against IL-1 or IL-1 had no effect on TGF-1 production excludes the involvement of IL-1 cytokine in the response to NE. Experiments with IL-1RI and IL-1RII neutralizing antibodies further exclude these receptors from targets of NE. Taken together, our data suggest that NE stimulate TGF-1 expression through a NF-B-mediated mechanism.
Toll like receptors (TLRs) compose a large family with 10 members (TLR1-10) (30-32), which play an important role in the recognition of microbial components, with subsequent activation of innate immunity leading to development of adaptive immune responses (33) . The prototypical TLR is TLR4, which is the recognized receptor for lipopolysaccharide (LPS) (34) . To transmit its signal, TLRs recruit adaptor proteins such as MyD88 (myeloid differentiation factor 88) that leads to phosphorylation of I B, allowing nuclear translocation of NF-B. NE has been shown to stimulate IL-8 release from human bronchial epithelial cells through TLR4 (23) and the downstream IRAK/MyD88/TRAF6 pathway to activate NF-B (20) . In the present study, NE decreased TLR4 expression on ASM cells with increased expression of IRAK and MyD88, and then subsequent enhanced IRAK co-precipitation with MyD88, indicating activation and increased recruitment of IRAK to MyD88. Treatment with LPS was also found to decrease TLR4 surface expression on ASM cells in this study. NE was also reported to decrease TLR4 surface expression on bronchial epithelium to activate NF-B (35) . Thus, the mechanism by which NE decreased TLR4 surface expression may be similar to that of LPS-induced TLR4 internalisation or alternatively could be a result of cleavage by NE (35, 36) .
Pretreatment with a TLR4 blocking antibody attenuates NE-induced TGF-1 production confirming TLR4 is mediated in this response. PAR-2 has also been reported to mediate TGF-1 synthesis at a post-transcriptional level through activation of the ERK MAP kinase cascade (37). In the present study, NE did not affect the surface expression of PAR2. Furthermore, the NE-stimulated TGF-1 secretion was not affected by the specific ERK inhibitor PD98059 or a blocking antibody against PAR2, precluding the involvement of PAR2 in this response. Taken together, our present results indicate NE activates IRAK/MyD88 through TLR4 in ASM cells to activate NF-B pathways.
TGF-1 is a potent profibrotic cytokine and has been suggested to play a role in the fibrotic changes occurring within asthmatic airways (16, 38) . Although the predominant effect of TGF-1 on cell proliferation is inhibitory, the mitogenic action were untreated or stimulated with 0.5 µg/ml NE for 6 hours, with or without pretreatment with pyrrolidine dithiocarbamate (PDTC, 1 mM), aspirin (Asp, 2.5 mM), or sodium salicylate (NaSal, 2.5 mM) for 30 minutes. Data are mean ± SE. #p < 0.01 compared with the control group (n = 5); **p < 0.01 compared with 0.5µg/ml of NE (n=5); p < 0.05 compared with 0.5 µg/ml of NE (n=5). Control Elastase TGF-1 (pg/ml)
